21Aug 2023
Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study

Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study

A recent study on Myasthenia gravis (MG) in elderly patients revealed concerning findings. The study analyzed data from 138 patients diagnosed with MG after the age of 70. While most patients showed improved symptoms with treatment, 41% experienced treatment adverse effects (TAE), with severe TAE seen in 14%. Tragically, 5.1% of patients died, including cases of MG-related respiratory failure and treatment-related complications such as sepsis and brain toxoplasmosis. These complications were more common in patients treated with azathioprine. The study underscores the substantial iatrogenic (treatment-induced) risks associated with MG in elderly individuals, warranting careful consideration of treatment options.

  • #neurology

Like

Save

Share